Home Health Serious skin reactions when taking the anticancer drug atezolizumab

Serious skin reactions when taking the anticancer drug atezolizumab

0

Atezolizumab is a monoclonal antibody drug used to treat urinary tract carcinoma, non-small cell lung cancer, 3-negative breast cancer, small cell lung cancer, and carcinoma. liver cells.
Serious adverse skin reactions are a group of immunocompromised drug rashes. Although rare, these reactions are potentially fatal, including acute systemic pustules, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug-induced hypersensitivity syndrome to eosinophilia. and systemic symptoms (DRESS).

Analysis conducted on Roche’s pharmacovigilance database showed 99 cases of serious adverse skin reactions, including 36 cases confirmed by histopathology or according to a specialist’s diagnosis. , in patients taking atezolizumab. About 23,654 patients who were treated in clinical trials and 106,316 after the drug was licensed for circulation in the market were exposed to atezolizumab as of May 17, 2020.

The incidence of serious adverse skin reactions based on laboratory clinical trials with atezolizumab as monotherapy and combination was 0.7% and 0.6%, respectively. A death from toxic epidermal necrolysis has been reported in a 77-year-old patient treated with atezolizumab as monotherapy.

Concerned about the above serious adverse reactions that may occur when taking the drug, Roche Company recommends: If serious adverse skin reactions are suspected, the patient should be referred to a specialist. to be diagnosed and handled appropriately. Treatment with atezolizumab should be discontinued if Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected. Treatment with atezolizumab should be permanently discontinued if Stevens-Johnson syndrome or toxic epidermal necrolysis is confirmed, as well as any adverse skin reactions or severe rash at grade 4. Atezolizumab should be used. Caution is given to patients with a history of serious or life-threatening adverse skin reactions during previous treatment with another immunostimulating anticancer drug.

MSc. DS. Chu Thanh Hang

((According to ansm, 4/2021))

NO COMMENTS